Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
Authors:
- Leonor DrouinLDLeonor Drouin
- Benedetta GuaniBenedetta Guani
- Vincent BalayaVincent Balaya
- Henri AzaïsHAHenri Azaïs
- Sarah BetrianSBSarah Betrian
- Pierre-Adrien BolzePBPierre-Adrien Bolze
- Yohann DabiYDYohann Dabi
- Yohan KerbageYKYohan Kerbage
- Claire SansonCSClaire Sanson
- François ZaccariniFZFrançois Zaccarini
- Patrice MathevetPMPatrice Mathevet
- Fabrice LécuruFLFabrice Lécuru
Open Access
- 21 October 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 4829
Abstract
Background: The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer. Method: a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (National Investigators Group for Ovarian and Breast Cancer Studies in France) and FRANCOGYN (French research group in oncological and gynaecological surgery). Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed. Results: a total of 107 participants responded to emailed surveys. Most of the respondents were obstetrician-gynaecologists (37.4%), surgical oncologists (34.6%) and medical oncologists (17.8%). According to most (76.8%) participants, less than 50% of patients were eligible for primary debulking surgery (PDS). The LION study criteria were applied in 69.5% of cases during PDS and 39% after chemotherapy. The timing of BRCA testing was very heterogeneous and ranged from 1 to 6 months. The use of bevacizumab as an adjuvant schedule was lower in cases of no residual disease (for 54.5% of respondents) compared to cases of residual disease (for 63.6% of respondents). In cases of BRCA1-2 mutations, olaparib was given by 75.8–84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases. Conclusion: this survey provides an extensive and a unique review of current French practices in the management of patients with advanced epithelial ovarian cancer in 2021.Keywords
This publication has 45 references indexed in Scilit:
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic OncologistsGynecologic Oncology, 2010
- Management of rare ovarian cancers: The experience of the French website «Observatory for rare malignant tumours of the ovaries» by the GINECO group: Interim analysis of the first 100 patientsGynecologic Oncology, 2010
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter TrialsJournal of Clinical Oncology, 2010
- Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigmGynecologic Oncology, 2009
- What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology, 2006
- Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2005
- What Are the Current Surgical Objectives, Strategies, and Technical Capabilities of Gynecologic Oncologists Treating Advanced Epithelial Ovarian Cancer?Gynecologic Oncology, 2001